Literature DB >> 26101579

Leveraging the Pre-DFG Residue Thr-406 To Obtain High Kinase Selectivity in an Aminopyrazole-Type PAK1 Inhibitor Series.

Joachim Rudolph1, Ignacio Aliagas1, James J Crawford1, Simon Mathieu1, Wendy Lee1, Qi Chao2, Ping Dong2, Lionel Rouge1, Weiru Wang1, Christopher Heise1, Lesley J Murray1, Hank La1, Yanzhou Liu1, Gerard Manning1, François Diederich3, Klaus P Hoeflich1.   

Abstract

To increase kinase selectivity in an aminopyrazole-based PAK1 inhibitor series, analogues were designed to interact with the PAK1 deep-front pocket pre-DFG residue Thr-406, a residue that is hydrophobic in most kinases. This goal was achieved by installing lactam head groups to the aminopyrazole hinge binding moiety. The corresponding analogues represent the most kinase selective ATP-competitive Group I PAK inhibitors described to date. Hydrogen bonding with the Thr-406 side chain was demonstrated by X-ray crystallography, and inhibitory activities, particularly against kinases with hydrophobic pre-DFG residues, were mitigated. Leveraging hydrogen bonding side chain interactions with polar pre-DFG residues is unprecedented, and similar strategies should be applicable to other appropriate kinases.

Entities:  

Keywords:  PAK1 kinase; Pre-DFG residue; aminopyrazole

Year:  2015        PMID: 26101579      PMCID: PMC4468403          DOI: 10.1021/acsmedchemlett.5b00151

Source DB:  PubMed          Journal:  ACS Med Chem Lett        ISSN: 1948-5875            Impact factor:   4.345


  11 in total

1.  Highly Efficient Au(I)-catalyzed intramolecular addition of beta-ketoamide to unactivated alkenes.

Authors:  Cong-Ying Zhou; Chi-Ming Che
Journal:  J Am Chem Soc       Date:  2007-04-18       Impact factor: 15.419

Review 2.  PAK signalling during the development and progression of cancer.

Authors:  Maria Radu; Galina Semenova; Rachelle Kosoff; Jonathan Chernoff
Journal:  Nat Rev Cancer       Date:  2014-01       Impact factor: 60.716

3.  Back pocket flexibility provides group II p21-activated kinase (PAK) selectivity for type I 1/2 kinase inhibitors.

Authors:  Steven T Staben; Jianwen A Feng; Karen Lyle; Marcia Belvin; Jason Boggs; Jason D Burch; Ching-ching Chua; Haifeng Cui; Antonio G DiPasquale; Lori S Friedman; Christopher Heise; Hartmut Koeppen; Adrian Kotey; Robert Mintzer; Angela Oh; David Allen Roberts; Lionel Rouge; Joachim Rudolph; Christine Tam; Weiru Wang; Yisong Xiao; Amy Young; Yamin Zhang; Klaus P Hoeflich
Journal:  J Med Chem       Date:  2014-02-04       Impact factor: 7.446

4.  Targeting p21-activated kinase 1 (PAK1) to induce apoptosis of tumor cells.

Authors:  Christy C Ong; Adrian M Jubb; Peter M Haverty; Wei Zhou; Victoria Tran; Tom Truong; Helen Turley; Tom O'Brien; Domagoj Vucic; Adrian L Harris; Marcia Belvin; Lori S Friedman; Elizabeth M Blackwood; Hartmut Koeppen; Klaus P Hoeflich
Journal:  Proc Natl Acad Sci U S A       Date:  2011-04-11       Impact factor: 11.205

5.  Azaindole-Based Inhibitors of Cdc7 Kinase: Impact of the Pre-DFG Residue, Val 195.

Authors:  Yunsong Tong; Kent D Stewart; Alan S Florjancic; John E Harlan; Philip J Merta; Magdalena Przytulinska; Nirupama Soni; Kerren K Swinger; Haizhong Zhu; Eric F Johnson; Alexander R Shoemaker; Thomas D Penning
Journal:  ACS Med Chem Lett       Date:  2013-01-15       Impact factor: 4.345

6.  Structure of PAK1 in an autoinhibited conformation reveals a multistage activation switch.

Authors:  M Lei; W Lu; W Meng; M C Parrini; M J Eck; B J Mayer; S C Harrison
Journal:  Cell       Date:  2000-08-04       Impact factor: 41.582

7.  Inhibitors of p21-activated kinases (PAKs).

Authors:  Joachim Rudolph; James J Crawford; Klaus P Hoeflich; Weiru Wang
Journal:  J Med Chem       Date:  2014-12-03       Impact factor: 7.446

8.  The genomic and transcriptomic architecture of 2,000 breast tumours reveals novel subgroups.

Authors:  Christina Curtis; Sohrab P Shah; Suet-Feung Chin; Gulisa Turashvili; Oscar M Rueda; Mark J Dunning; Doug Speed; Andy G Lynch; Shamith Samarajiwa; Yinyin Yuan; Stefan Gräf; Gavin Ha; Gholamreza Haffari; Ali Bashashati; Roslin Russell; Steven McKinney; Anita Langerød; Andrew Green; Elena Provenzano; Gordon Wishart; Sarah Pinder; Peter Watson; Florian Markowetz; Leigh Murphy; Ian Ellis; Arnie Purushotham; Anne-Lise Børresen-Dale; James D Brenton; Simon Tavaré; Carlos Caldas; Samuel Aparicio
Journal:  Nature       Date:  2012-04-18       Impact factor: 49.962

9.  PAK family kinases: Physiological roles and regulation.

Authors:  Zhuo-Shen Zhao; Ed Manser
Journal:  Cell Logist       Date:  2012-04-01

10.  PAK1 is a breast cancer oncogene that coordinately activates MAPK and MET signaling.

Authors:  Y Shrestha; E J Schafer; J S Boehm; S R Thomas; F He; J Du; S Wang; J Barretina; B A Weir; J J Zhao; K Polyak; T R Golub; R Beroukhim; W C Hahn
Journal:  Oncogene       Date:  2011-11-21       Impact factor: 9.867

View more
  3 in total

1.  Optimization of Highly Kinase Selective Bis-anilino Pyrimidine PAK1 Inhibitors.

Authors:  William McCoull; Edward J Hennessy; Kevin Blades; Claudio Chuaqui; James E Dowling; Andrew D Ferguson; Frederick W Goldberg; Nicholas Howe; Christopher R Jones; Paul D Kemmitt; Gillian Lamont; Jeffrey G Varnes; Richard A Ward; Bin Yang
Journal:  ACS Med Chem Lett       Date:  2016-09-14       Impact factor: 4.345

2.  Synthesis of aminopyrazole analogs and their evaluation as CDK inhibitors for cancer therapy.

Authors:  Sandeep Rana; Yogesh A Sonawane; Margaret A Taylor; Smitha Kizhake; Muhammad Zahid; Amarnath Natarajan
Journal:  Bioorg Med Chem Lett       Date:  2018-10-15       Impact factor: 2.823

3.  Development of a potent and selective chemical probe for the pleiotropic kinase CK2.

Authors:  Carrow I Wells; David H Drewry; Julie E Pickett; Amelie Tjaden; Andreas Krämer; Susanne Müller; Laszlo Gyenis; Daniel Menyhart; David W Litchfield; Stefan Knapp; Alison D Axtman
Journal:  Cell Chem Biol       Date:  2021-01-22       Impact factor: 8.116

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.